ID

13642

Descripción

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion; ODM derived from: https://clinicaltrials.gov/show/NCT01349491

Link

https://clinicaltrials.gov/show/NCT01349491

Palabras clave

  1. 22/2/16 22/2/16 -
Subido en

22 de febrero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Atrial Fibrillation NCT01349491

Eligibility Atrial Fibrillation NCT01349491

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female with persistent atrial fibrillation, aged 21 or older
Descripción

atrial fibrillation; age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004238
UMLS CUI [2]
C0001779
duration of atrial fibrillation less than one year
Descripción

atrial fibrillation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004238
the patient does not have any contraindications for anticoagulation
Descripción

Anticoagulation contraindicated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1531588
the patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits
Descripción

compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1321605
the patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
the patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.
Descripción

laboratory value; patient safety

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011911
UMLS CUI [2]
C1113679
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
any contraindication for anticoagulation
Descripción

Anticoagulation contraindicated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1531588
new york heart association class iv heart failure
Descripción

new york heart association class iv

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1319796
currently taking anti-arrhythmic drugs
Descripción

anti-arrhythmic drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003195
chronic kidney disease (serum creatinine less than 2.5mg/dl) or severe liver dysfunction
Descripción

chronic kidney disease; Liver Dysfunction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1561643
UMLS CUI [2]
C0086565
pregnancy/nursing
Descripción

pregnant; lactating

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2828358
UMLS CUI [2]
C0549206
prolonged qt interval (>500ms)
Descripción

prolonged qt interval

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151878
taking other medications known to prolong the qt interval
Descripción

medication prolonged qt interval

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0151878
taking other medications known to affect the metabolism of ranolazine
Descripción

ranolazine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0073633

Similar models

Eligibility Atrial Fibrillation NCT01349491

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
atrial fibrillation; age
Item
male or female with persistent atrial fibrillation, aged 21 or older
boolean
C0004238 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
atrial fibrillation
Item
duration of atrial fibrillation less than one year
boolean
C0004238 (UMLS CUI [1])
Anticoagulation contraindicated
Item
the patient does not have any contraindications for anticoagulation
boolean
C1531588 (UMLS CUI [1])
compliance
Item
the patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
the patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.
boolean
C0021430 (UMLS CUI [1])
laboratory value; patient safety
Item
the patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.
boolean
C0011911 (UMLS CUI [1])
C1113679 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Anticoagulation contraindicated
Item
any contraindication for anticoagulation
boolean
C1531588 (UMLS CUI [1])
new york heart association class iv
Item
new york heart association class iv heart failure
boolean
C1319796 (UMLS CUI [1])
anti-arrhythmic drugs
Item
currently taking anti-arrhythmic drugs
boolean
C0003195 (UMLS CUI [1])
chronic kidney disease; Liver Dysfunction
Item
chronic kidney disease (serum creatinine less than 2.5mg/dl) or severe liver dysfunction
boolean
C1561643 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
pregnant; lactating
Item
pregnancy/nursing
boolean
C2828358 (UMLS CUI [1])
C0549206 (UMLS CUI [2])
prolonged qt interval
Item
prolonged qt interval (>500ms)
boolean
C0151878 (UMLS CUI [1])
medication prolonged qt interval
Item
taking other medications known to prolong the qt interval
boolean
C0013227 (UMLS CUI [1,1])
C0151878 (UMLS CUI [1,2])
ranolazine
Item
taking other medications known to affect the metabolism of ranolazine
boolean
C0073633 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial